Steatohepatitis/Metabolic Liver Disease News

VIENNA — A new, open-access simulator gives providers the tools to show natural progression of non-alcoholic fatty liver disease to their patients using personalized factors, according to an expert at the International Liver Congress.

VIENNA — Lubiprostone was tolerable and improved hepatic markers among patients with nonalcoholic fatty liver disease, according to data presented at the International Liver Congress 2019.

VIENNA — Young adults around aged 24 years showed a high prevalence of nonalcoholic fatty liver disease, with progression increasing with age even in this small birth cohort, according to new data presented during the International Liver Congress 2019.

VIENNA — Despite missing one of the two primary endpoints set with the FDA, Ocaliva produced antifibrotic effects in a dose-dependent manner in a large, prospective study of patients with non-alcoholic steatohepatitis presented during the International Liver Congress 2019.

VIENNA — GKT831 achieved rapid dose- and time-dependent reductions in markers of cholestatic bile duct disease and liver injury in patients with primary biliary cholangitis who had an inadequate response to ursodeoxycholic acid, according to a presentation at International Liver Conference 2019.

VIENNA — As HIV reaches new levels of control and hepatitis C virus treatments give cures, providers must be aware that non-alcoholic fatty liver disease is on the rise in the population with HIV as it is in the general population.

VIENNA — Patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis showed progression to advanced liver disease within 10 years of diagnosis as well as increased risk for mortality, according to new data presented during the International Liver Congress 2019.

Poxel SA announced favorable results from its phase 1a two-part study of PXL065 compared with Actos for the treatment of nonalcoholic steatohepatitis, according to a press release.

Alnylam Pharmaceuticals announced a collaboration with Regeneron to discover, develop and commercialize new RNA interference therapeutics for a broad range of diseases by addressing disease targets including those expressed in the liver, according to a press release.

Prevalence screening for lysosomal acid lipase deficiency and its mild form that can mimic nonalcoholic fatty liver disease showed that it is an “ultra-rare” disorder but may warrant investigation in second-line metabolic screening.